MedTrace Logo

Resveratrol for Endothelial Dysfunction and Metabolic Control in Type 2 Diabetes

NCT07569744 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-05-11

No results posted yet for this study

Summary

Type 2 diabetes mellitus is associated with endothelial dysfunction, which contributes to increased cardiovascular risk. Chronic hyperglycemia induces oxidative stress and reduces nitric oxide bioavailability, leading to impaired endothelial function. Resveratrol, a natural polyphenol with antioxidant and anti-inflammatory properties, has been shown to improve endothelial function in experimental studies.

This randomized controlled trial aims to evaluate the effectiveness of resveratrol supplementation in improving endothelial dysfunction and metabolic control in patients with type 2 diabetes mellitus. Endothelial function will be assessed using flow-mediated dilatation (FMD) of the brachial artery and serum endothelial nitric oxide synthase (eNOS) levels. Metabolic parameters including fasting blood glucose, postprandial glucose, HbA1c, and lipid profile will also be evaluated.

Conditions

Interventions

DRUG

Resveratrol

Resveratrol 50 mg administered orally once daily for 12 weeks.

DRUG

Placebo

Matching placebo administered orally once daily for 12 weeks.

Sponsors & Collaborators

  • Universitas Sriwijaya

    lead OTHER

Principal Investigators

  • Yulianto Kusnadi, MD, DR · Faculty of Medicine Universitas Sriwijaya / RSUP Dr. Mohammad Hoesin Palembang

  • Rita Sriwulandari, MD · Division of Endocrinology, FK UNSRI / RSMH Palembang

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2026-08-31
Completion
2026-10-31

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07569744 on ClinicalTrials.gov